Medicine and Dentistry
Transplantation
100%
Organ
72%
Plasma
63%
Gluconeogenesis
63%
Sodium Glucose Cotransporter 2 Inhibitor
63%
Patient
56%
Peptide
54%
Glucose
51%
Lung
42%
Liver
40%
Kidney
40%
Dapagliflozin
40%
Placebo
34%
Maturity Onset Diabetes of the Young
34%
Kidney Graft
34%
Hemoglobin A1c
34%
Program Evaluation
32%
Insulin
31%
Diabetes Mellitus
26%
Cardiovascular System
26%
Weight Loss
26%
Glucagon
23%
Combination Therapy
18%
Urinary System
17%
Glucosuria
17%
Kidney Denervation
17%
Cotransporter
17%
Blood
17%
Follow up
17%
Adult
17%
Glycemic
17%
Graft Failure
15%
Incidence
15%
Adverse Event
15%
Body Weight
15%
Diabetes
13%
Nausea
9%
Evaluation Study
9%
Population
9%
Glucagon-Like Peptide-1 Agonist
9%
Liver Graft
9%
Pancreatitis
9%
Assessment
9%
Adverse Drug Reaction
9%
Solid Organ Transplantation
9%
Antidiabetic Agent
9%
Organ Transplantation
9%
Insulin Treatment
9%
All Cause Mortality
7%
Kidney Transplantation
7%
Pharmacology, Toxicology and Pharmaceutical Science
Sodium Glucose Cotransporter 2 Inhibitor
63%
Peptide
54%
Receptor Agonist
54%
Hemoglobin A1c
34%
Diabetes Mellitus
34%
Glucose
17%
Incidence
15%
Adverse Event
15%
Graft Failure
15%
Pancreatitis
9%
Glucagon Like Peptide 1 Receptor Agonist
9%
Nausea
9%
Antidiabetic Agent
9%
Adverse Drug Reaction
9%
Hypoglycemia
7%
Heart Infarction
7%
All Cause Mortality
7%
Insulin
7%
Mortality
7%
Urinary Tract Infection
7%
Death
7%
Hypotension
7%
Nursing and Health Professions
Sodium Glucose Cotransporter 2 Inhibitor
63%
Transplantation
63%
Program Evaluation
23%
Adverse Event
15%
Hemoglobin A1c
15%
Graft Failure
15%
Body Weight
15%
Incidence
15%
Diabetes Mellitus
15%
Infarction
7%
Insulin
7%
Kidney Graft
7%
Kidney Transplantation
7%
Body Weight Loss
7%
Hypoglycemia
7%
Glucose Blood Level
7%
Death
7%
All Cause Mortality
7%
Follow up
7%
Body Mass
7%
Time
7%
Mortality
7%
Urinary Tract Infection
7%
Hypotension
7%